The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bio Similars/Subsequent Entry Biologic Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Bio Similars/Subsequent Entry Biologic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Bio Similars/Subsequent Entry Biologic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Tumor accounting for % of the Bio Similars/Subsequent Entry Biologic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monoclonal Antibodies segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Bio Similars/Subsequent Entry Biologic include Sun Pharma, Synthon Pharmaceuticals, Teva Pharmaceutical Industries, LG Life Sciences, and Celltrion Biocon, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Bio Similars/Subsequent Entry Biologic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Market segment by Application, can be divided into
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Market segment by players, this report covers
Sun Pharma
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck
Biogen idec
Genentech (Roche)
Pfizer
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
AbbVie
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
3sbio
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Bio Similars/Subsequent Entry Biologic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Bio Similars/Subsequent Entry Biologic, with revenue, gross margin and global market share of Bio Similars/Subsequent Entry Biologic from 2019 to 2022.
Chapter 3, the Bio Similars/Subsequent Entry Biologic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Bio Similars/Subsequent Entry Biologic market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Bio Similars/Subsequent Entry Biologic research findings and conclusion, appendix and data source.
Geographical Area
Global
The Bio Similars/Subsequent Entry Biologic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Bio Similars/Subsequent Entry Biologic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Tumor accounting for % of the Bio Similars/Subsequent Entry Biologic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monoclonal Antibodies segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Bio Similars/Subsequent Entry Biologic include Sun Pharma, Synthon Pharmaceuticals, Teva Pharmaceutical Industries, LG Life Sciences, and Celltrion Biocon, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Bio Similars/Subsequent Entry Biologic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Market segment by Application, can be divided into
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Market segment by players, this report covers
Sun Pharma
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck
Biogen idec
Genentech (Roche)
Pfizer
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
AbbVie
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
3sbio
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Bio Similars/Subsequent Entry Biologic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Bio Similars/Subsequent Entry Biologic, with revenue, gross margin and global market share of Bio Similars/Subsequent Entry Biologic from 2019 to 2022.
Chapter 3, the Bio Similars/Subsequent Entry Biologic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Bio Similars/Subsequent Entry Biologic market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Bio Similars/Subsequent Entry Biologic research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Bio Similars/Subsequent Entry Biologic
1.2 Classification of Bio Similars/Subsequent Entry Biologic by Type
1.2.1 Overview: Global Bio Similars/Subsequent Entry Biologic Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type in 2021
1.2.3 Monoclonal Antibodies
1.2.4 Interferon
1.2.5 Erythropoietin
1.2.6 Insulin
1.2.7 Vaccines
1.2.8 Other
1.3 Global Bio Similars/Subsequent Entry Biologic Market by Application
1.3.1 Overview: Global Bio Similars/Subsequent Entry Biologic Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Other
1.4 Global Bio Similars/Subsequent Entry Biologic Market Size & Forecast
1.5 Global Bio Similars/Subsequent Entry Biologic Market Size and Forecast by Region
1.5.1 Global Bio Similars/Subsequent Entry Biologic Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Bio Similars/Subsequent Entry Biologic Market Size by Region, (2017-2022)
1.5.3 North America Bio Similars/Subsequent Entry Biologic Market Size and Prospect (2017-2028)
1.5.4 Europe Bio Similars/Subsequent Entry Biologic Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size and Prospect (2017-2028)
1.5.6 South America Bio Similars/Subsequent Entry Biologic Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Bio Similars/Subsequent Entry Biologic Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Bio Similars/Subsequent Entry Biologic Market Drivers
1.6.2 Bio Similars/Subsequent Entry Biologic Market Restraints
1.6.3 Bio Similars/Subsequent Entry Biologic Trends Analysis
2 Company Profiles
2.1 Sun Pharma
2.1.1 Sun Pharma Details
2.1.2 Sun Pharma Major Business
2.1.3 Sun Pharma Bio Similars/Subsequent Entry Biologic Product and Solutions
2.1.4 Sun Pharma Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Sun Pharma Recent Developments and Future Plans
2.2 Synthon Pharmaceuticals
2.2.1 Synthon Pharmaceuticals Details
2.2.2 Synthon Pharmaceuticals Major Business
2.2.3 Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Product and Solutions
2.2.4 Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Synthon Pharmaceuticals Recent Developments and Future Plans
2.3 Teva Pharmaceutical Industries
2.3.1 Teva Pharmaceutical Industries Details
2.3.2 Teva Pharmaceutical Industries Major Business
2.3.3 Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Product and Solutions
2.3.4 Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.4 LG Life Sciences
2.4.1 LG Life Sciences Details
2.4.2 LG Life Sciences Major Business
2.4.3 LG Life Sciences Bio Similars/Subsequent Entry Biologic Product and Solutions
2.4.4 LG Life Sciences Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 LG Life Sciences Recent Developments and Future Plans
2.5 Celltrion Biocon
2.5.1 Celltrion Biocon Details
2.5.2 Celltrion Biocon Major Business
2.5.3 Celltrion Biocon Bio Similars/Subsequent Entry Biologic Product and Solutions
2.5.4 Celltrion Biocon Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Celltrion Biocon Recent Developments and Future Plans
2.6 Hospira
2.6.1 Hospira Details
2.6.2 Hospira Major Business
2.6.3 Hospira Bio Similars/Subsequent Entry Biologic Product and Solutions
2.6.4 Hospira Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Hospira Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Bio Similars/Subsequent Entry Biologic Product and Solutions
2.7.4 Merck Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Merck Recent Developments and Future Plans
2.8 Biogen idec
2.8.1 Biogen idec Details
2.8.2 Biogen idec Major Business
2.8.3 Biogen idec Bio Similars/Subsequent Entry Biologic Product and Solutions
2.8.4 Biogen idec Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Biogen idec Recent Developments and Future Plans
2.9 Genentech (Roche)
2.9.1 Genentech (Roche) Details
2.9.2 Genentech (Roche) Major Business
2.9.3 Genentech (Roche) Bio Similars/Subsequent Entry Biologic Product and Solutions
2.9.4 Genentech (Roche) Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Genentech (Roche) Recent Developments and Future Plans
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Bio Similars/Subsequent Entry Biologic Product and Solutions
2.10.4 Pfizer Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Pfizer Recent Developments and Future Plans
2.11 Celltrion
2.11.1 Celltrion Details
2.11.2 Celltrion Major Business
2.11.3 Celltrion Bio Similars/Subsequent Entry Biologic Product and Solutions
2.11.4 Celltrion Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Celltrion Recent Developments and Future Plans
2.12 Biocon
2.12.1 Biocon Details
2.12.2 Biocon Major Business
2.12.3 Biocon Bio Similars/Subsequent Entry Biologic Product and Solutions
2.12.4 Biocon Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Biocon Recent Developments and Future Plans
2.13 Amgen
2.13.1 Amgen Details
2.13.2 Amgen Major Business
2.13.3 Amgen Bio Similars/Subsequent Entry Biologic Product and Solutions
2.13.4 Amgen Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Amgen Recent Developments and Future Plans
2.14 Samsung Biologics
2.14.1 Samsung Biologics Details
2.14.2 Samsung Biologics Major Business
2.14.3 Samsung Biologics Bio Similars/Subsequent Entry Biologic Product and Solutions
2.14.4 Samsung Biologics Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Samsung Biologics Recent Developments and Future Plans
2.15 Mylan
2.15.1 Mylan Details
2.15.2 Mylan Major Business
2.15.3 Mylan Bio Similars/Subsequent Entry Biologic Product and Solutions
2.15.4 Mylan Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Mylan Recent Developments and Future Plans
2.16 Dr. Reddy's Laboratories
2.16.1 Dr. Reddy's Laboratories Details
2.16.2 Dr. Reddy's Laboratories Major Business
2.16.3 Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Product and Solutions
2.16.4 Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Dr. Reddy's Laboratories Recent Developments and Future Plans
2.17 Stada Arzneimittel AG
2.17.1 Stada Arzneimittel AG Details
2.17.2 Stada Arzneimittel AG Major Business
2.17.3 Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Product and Solutions
2.17.4 Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Stada Arzneimittel AG Recent Developments and Future Plans
2.18 AbbVie
2.18.1 AbbVie Details
2.18.2 AbbVie Major Business
2.18.3 AbbVie Bio Similars/Subsequent Entry Biologic Product and Solutions
2.18.4 AbbVie Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 AbbVie Recent Developments and Future Plans
2.19 Sanofi-Aventis
2.19.1 Sanofi-Aventis Details
2.19.2 Sanofi-Aventis Major Business
2.19.3 Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Product and Solutions
2.19.4 Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Sanofi-Aventis Recent Developments and Future Plans
2.20 Johnson & Johnson
2.20.1 Johnson & Johnson Details
2.20.2 Johnson & Johnson Major Business
2.20.3 Johnson & Johnson Bio Similars/Subsequent Entry Biologic Product and Solutions
2.20.4 Johnson & Johnson Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Johnson & Johnson Recent Developments and Future Plans
2.21 Novo Nordisk
2.21.1 Novo Nordisk Details
2.21.2 Novo Nordisk Major Business
2.21.3 Novo Nordisk Bio Similars/Subsequent Entry Biologic Product and Solutions
2.21.4 Novo Nordisk Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Novo Nordisk Recent Developments and Future Plans
2.22 Eli Lilly
2.22.1 Eli Lilly Details
2.22.2 Eli Lilly Major Business
2.22.3 Eli Lilly Bio Similars/Subsequent Entry Biologic Product and Solutions
2.22.4 Eli Lilly Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Eli Lilly Recent Developments and Future Plans
2.23 Novartis
2.23.1 Novartis Details
2.23.2 Novartis Major Business
2.23.3 Novartis Bio Similars/Subsequent Entry Biologic Product and Solutions
2.23.4 Novartis Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 Novartis Recent Developments and Future Plans
2.24 3sbio
2.24.1 3sbio Details
2.24.2 3sbio Major Business
2.24.3 3sbio Bio Similars/Subsequent Entry Biologic Product and Solutions
2.24.4 3sbio Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.24.5 3sbio Recent Developments and Future Plans
2.25 Biotech
2.25.1 Biotech Details
2.25.2 Biotech Major Business
2.25.3 Biotech Bio Similars/Subsequent Entry Biologic Product and Solutions
2.25.4 Biotech Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.25.5 Biotech Recent Developments and Future Plans
2.26 Gelgen
2.26.1 Gelgen Details
2.26.2 Gelgen Major Business
2.26.3 Gelgen Bio Similars/Subsequent Entry Biologic Product and Solutions
2.26.4 Gelgen Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.26.5 Gelgen Recent Developments and Future Plans
2.27 Innovent
2.27.1 Innovent Details
2.27.2 Innovent Major Business
2.27.3 Innovent Bio Similars/Subsequent Entry Biologic Product and Solutions
2.27.4 Innovent Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.27.5 Innovent Recent Developments and Future Plans
2.28 Dong Bao
2.28.1 Dong Bao Details
2.28.2 Dong Bao Major Business
2.28.3 Dong Bao Bio Similars/Subsequent Entry Biologic Product and Solutions
2.28.4 Dong Bao Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.28.5 Dong Bao Recent Developments and Future Plans
2.29 Ganlee
2.29.1 Ganlee Details
2.29.2 Ganlee Major Business
2.29.3 Ganlee Bio Similars/Subsequent Entry Biologic Product and Solutions
2.29.4 Ganlee Bio Similars/Subsequent Entry Biologic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.29.5 Ganlee Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Bio Similars/Subsequent Entry Biologic Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Bio Similars/Subsequent Entry Biologic Players Market Share in 2021
3.2.2 Top 10 Bio Similars/Subsequent Entry Biologic Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Bio Similars/Subsequent Entry Biologic Players Head Office, Products and Services Provided
3.4 Bio Similars/Subsequent Entry Biologic Mergers & Acquisitions
3.5 Bio Similars/Subsequent Entry Biologic New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Bio Similars/Subsequent Entry Biologic Revenue and Market Share by Type (2017-2022)
4.2 Global Bio Similars/Subsequent Entry Biologic Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Application (2017-2022)
5.2 Global Bio Similars/Subsequent Entry Biologic Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2028)
6.2 North America Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2028)
6.3 North America Bio Similars/Subsequent Entry Biologic Market Size by Country
6.3.1 North America Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2028)
6.3.2 United States Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
6.3.3 Canada Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
6.3.4 Mexico Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2028)
7.2 Europe Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2028)
7.3 Europe Bio Similars/Subsequent Entry Biologic Market Size by Country
7.3.1 Europe Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2028)
7.3.2 Germany Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
7.3.3 France Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
7.3.5 Russia Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
7.3.6 Italy Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2028)
8.2 Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2028)
8.3 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Region
8.3.1 Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Region (2017-2028)
8.3.2 China Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
8.3.3 Japan Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
8.3.4 South Korea Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
8.3.5 India Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
8.3.7 Australia Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2028)
9.2 South America Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2028)
9.3 South America Bio Similars/Subsequent Entry Biologic Market Size by Country
9.3.1 South America Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2028)
9.3.2 Brazil Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
9.3.3 Argentina Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2028)
10.2 Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2028)
10.3 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Country
10.3.1 Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2028)
10.3.2 Turkey Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
10.3.4 UAE Bio Similars/Subsequent Entry Biologic Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Bio Similars/Subsequent Entry Biologic Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Bio Similars/Subsequent Entry Biologic Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Bio Similars/Subsequent Entry Biologic Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Bio Similars/Subsequent Entry Biologic Revenue (USD Million) by Region (2017-2022)
Table 5. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Region (2023-2028)
Table 6. Sun Pharma Corporate Information, Head Office, and Major Competitors
Table 7. Sun Pharma Major Business
Table 8. Sun Pharma Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 9. Sun Pharma Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Synthon Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Synthon Pharmaceuticals Major Business
Table 12. Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 13. Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 15. Teva Pharmaceutical Industries Major Business
Table 16. Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 17. Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. LG Life Sciences Corporate Information, Head Office, and Major Competitors
Table 19. LG Life Sciences Major Business
Table 20. LG Life Sciences Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 21. LG Life Sciences Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Celltrion Biocon Corporate Information, Head Office, and Major Competitors
Table 23. Celltrion Biocon Major Business
Table 24. Celltrion Biocon Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 25. Celltrion Biocon Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Hospira Corporate Information, Head Office, and Major Competitors
Table 27. Hospira Major Business
Table 28. Hospira Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 29. Hospira Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 33. Merck Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Biogen idec Corporate Information, Head Office, and Major Competitors
Table 35. Biogen idec Major Business
Table 36. Biogen idec Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 37. Biogen idec Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Genentech (Roche) Corporate Information, Head Office, and Major Competitors
Table 39. Genentech (Roche) Major Business
Table 40. Genentech (Roche) Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 41. Genentech (Roche) Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Pfizer Corporate Information, Head Office, and Major Competitors
Table 43. Pfizer Major Business
Table 44. Pfizer Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 45. Pfizer Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Celltrion Corporate Information, Head Office, and Major Competitors
Table 47. Celltrion Major Business
Table 48. Celltrion Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 49. Celltrion Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Biocon Corporate Information, Head Office, and Major Competitors
Table 51. Biocon Major Business
Table 52. Biocon Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 53. Biocon Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Amgen Corporate Information, Head Office, and Major Competitors
Table 55. Amgen Major Business
Table 56. Amgen Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 57. Amgen Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Samsung Biologics Corporate Information, Head Office, and Major Competitors
Table 59. Samsung Biologics Major Business
Table 60. Samsung Biologics Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 61. Samsung Biologics Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Mylan Corporate Information, Head Office, and Major Competitors
Table 63. Mylan Major Business
Table 64. Mylan Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 65. Mylan Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Dr. Reddy's Laboratories Corporate Information, Head Office, and Major Competitors
Table 67. Dr. Reddy's Laboratories Major Business
Table 68. Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 69. Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Stada Arzneimittel AG Corporate Information, Head Office, and Major Competitors
Table 71. Stada Arzneimittel AG Major Business
Table 72. Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 73. Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. AbbVie Corporate Information, Head Office, and Major Competitors
Table 75. AbbVie Major Business
Table 76. AbbVie Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 77. AbbVie Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Sanofi-Aventis Corporate Information, Head Office, and Major Competitors
Table 79. Sanofi-Aventis Major Business
Table 80. Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 81. Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 83. Johnson & Johnson Major Business
Table 84. Johnson & Johnson Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 85. Johnson & Johnson Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 87. Novo Nordisk Major Business
Table 88. Novo Nordisk Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 89. Novo Nordisk Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 91. Eli Lilly Major Business
Table 92. Eli Lilly Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 93. Eli Lilly Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. Novartis Corporate Information, Head Office, and Major Competitors
Table 95. Novartis Major Business
Table 96. Novartis Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 97. Novartis Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. 3sbio Corporate Information, Head Office, and Major Competitors
Table 99. 3sbio Major Business
Table 100. 3sbio Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 101. 3sbio Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 102. Biotech Corporate Information, Head Office, and Major Competitors
Table 103. Biotech Major Business
Table 104. Biotech Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 105. Biotech Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 106. Gelgen Corporate Information, Head Office, and Major Competitors
Table 107. Gelgen Major Business
Table 108. Gelgen Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 109. Gelgen Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 110. Innovent Corporate Information, Head Office, and Major Competitors
Table 111. Innovent Major Business
Table 112. Innovent Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 113. Innovent Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 114. Dong Bao Corporate Information, Head Office, and Major Competitors
Table 115. Dong Bao Major Business
Table 116. Dong Bao Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 117. Dong Bao Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 118. Ganlee Corporate Information, Head Office, and Major Competitors
Table 119. Ganlee Major Business
Table 120. Ganlee Bio Similars/Subsequent Entry Biologic Product and Solutions
Table 121. Ganlee Bio Similars/Subsequent Entry Biologic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 122. Global Bio Similars/Subsequent Entry Biologic Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 123. Global Bio Similars/Subsequent Entry Biologic Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 124. Breakdown of Bio Similars/Subsequent Entry Biologic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 125. Bio Similars/Subsequent Entry Biologic Players Head Office, Products and Services Provided
Table 126. Bio Similars/Subsequent Entry Biologic Mergers & Acquisitions in the Past Five Years
Table 127. Bio Similars/Subsequent Entry Biologic New Entrants and Expansion Plans
Table 128. Global Bio Similars/Subsequent Entry Biologic Revenue (USD Million) by Type (2017-2022)
Table 129. Global Bio Similars/Subsequent Entry Biologic Revenue Share by Type (2017-2022)
Table 130. Global Bio Similars/Subsequent Entry Biologic Revenue Forecast by Type (2023-2028)
Table 131. Global Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2022)
Table 132. Global Bio Similars/Subsequent Entry Biologic Revenue Forecast by Application (2023-2028)
Table 133. North America Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2022) & (USD Million)
Table 134. North America Bio Similars/Subsequent Entry Biologic Revenue by Type (2023-2028) & (USD Million)
Table 135. North America Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2022) & (USD Million)
Table 136. North America Bio Similars/Subsequent Entry Biologic Revenue by Application (2023-2028) & (USD Million)
Table 137. North America Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2022) & (USD Million)
Table 138. North America Bio Similars/Subsequent Entry Biologic Revenue by Country (2023-2028) & (USD Million)
Table 139. Europe Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2022) & (USD Million)
Table 140. Europe Bio Similars/Subsequent Entry Biologic Revenue by Type (2023-2028) & (USD Million)
Table 141. Europe Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2022) & (USD Million)
Table 142. Europe Bio Similars/Subsequent Entry Biologic Revenue by Application (2023-2028) & (USD Million)
Table 143. Europe Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2022) & (USD Million)
Table 144. Europe Bio Similars/Subsequent Entry Biologic Revenue by Country (2023-2028) & (USD Million)
Table 145. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2022) & (USD Million)
Table 146. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Type (2023-2028) & (USD Million)
Table 147. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2022) & (USD Million)
Table 148. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Application (2023-2028) & (USD Million)
Table 149. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Region (2017-2022) & (USD Million)
Table 150. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue by Region (2023-2028) & (USD Million)
Table 151. South America Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2022) & (USD Million)
Table 152. South America Bio Similars/Subsequent Entry Biologic Revenue by Type (2023-2028) & (USD Million)
Table 153. South America Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2022) & (USD Million)
Table 154. South America Bio Similars/Subsequent Entry Biologic Revenue by Application (2023-2028) & (USD Million)
Table 155. South America Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2022) & (USD Million)
Table 156. South America Bio Similars/Subsequent Entry Biologic Revenue by Country (2023-2028) & (USD Million)
Table 157. Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Type (2017-2022) & (USD Million)
Table 158. Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Type (2023-2028) & (USD Million)
Table 159. Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Application (2017-2022) & (USD Million)
Table 160. Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Application (2023-2028) & (USD Million)
Table 161. Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Country (2017-2022) & (USD Million)
Table 162. Middle East & Africa Bio Similars/Subsequent Entry Biologic Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Bio Similars/Subsequent Entry Biologic Picture
Figure 2. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type in 2021
Figure 3. Monoclonal Antibodies
Figure 4. Interferon
Figure 5. Erythropoietin
Figure 6. Insulin
Figure 7. Vaccines
Figure 8. Other
Figure 9. Bio Similars/Subsequent Entry Biologic Revenue Market Share by Application in 2021
Figure 10. Tumor Picture
Figure 11. Diabetes Picture
Figure 12. Cardiovascular Picture
Figure 13. Hemophilia Picture
Figure 14. Other Picture
Figure 15. Global Bio Similars/Subsequent Entry Biologic Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 16. Global Bio Similars/Subsequent Entry Biologic Revenue and Forecast (2017-2028) & (USD Million)
Figure 17. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Region (2017-2028)
Figure 18. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Region in 2021
Figure 19. North America Bio Similars/Subsequent Entry Biologic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Europe Bio Similars/Subsequent Entry Biologic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. South America Bio Similars/Subsequent Entry Biologic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Middle East and Africa Bio Similars/Subsequent Entry Biologic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 24. Bio Similars/Subsequent Entry Biologic Market Drivers
Figure 25. Bio Similars/Subsequent Entry Biologic Market Restraints
Figure 26. Bio Similars/Subsequent Entry Biologic Market Trends
Figure 27. Sun Pharma Recent Developments and Future Plans
Figure 28. Synthon Pharmaceuticals Recent Developments and Future Plans
Figure 29. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 30. LG Life Sciences Recent Developments and Future Plans
Figure 31. Celltrion Biocon Recent Developments and Future Plans
Figure 32. Hospira Recent Developments and Future Plans
Figure 33. Merck Recent Developments and Future Plans
Figure 34. Biogen idec Recent Developments and Future Plans
Figure 35. Genentech (Roche) Recent Developments and Future Plans
Figure 36. Pfizer Recent Developments and Future Plans
Figure 37. Celltrion Recent Developments and Future Plans
Figure 38. Biocon Recent Developments and Future Plans
Figure 39. Amgen Recent Developments and Future Plans
Figure 40. Samsung Biologics Recent Developments and Future Plans
Figure 41. Mylan Recent Developments and Future Plans
Figure 42. Dr. Reddy's Laboratories Recent Developments and Future Plans
Figure 43. Stada Arzneimittel AG Recent Developments and Future Plans
Figure 44. AbbVie Recent Developments and Future Plans
Figure 45. Sanofi-Aventis Recent Developments and Future Plans
Figure 46. Johnson & Johnson Recent Developments and Future Plans
Figure 47. Novo Nordisk Recent Developments and Future Plans
Figure 48. Eli Lilly Recent Developments and Future Plans
Figure 49. Novartis Recent Developments and Future Plans
Figure 50. 3sbio Recent Developments and Future Plans
Figure 51. Biotech Recent Developments and Future Plans
Figure 52. Gelgen Recent Developments and Future Plans
Figure 53. Innovent Recent Developments and Future Plans
Figure 54. Dong Bao Recent Developments and Future Plans
Figure 55. Ganlee Recent Developments and Future Plans
Figure 56. Global Bio Similars/Subsequent Entry Biologic Revenue Share by Players in 2021
Figure 57. Bio Similars/Subsequent Entry Biologic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 58. Global Top 3 Players Bio Similars/Subsequent Entry Biologic Revenue Market Share in 2021
Figure 59. Global Top 10 Players Bio Similars/Subsequent Entry Biologic Revenue Market Share in 2021
Figure 60. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 61. Global Bio Similars/Subsequent Entry Biologic Revenue Share by Type in 2021
Figure 62. Global Bio Similars/Subsequent Entry Biologic Market Share Forecast by Type (2023-2028)
Figure 63. Global Bio Similars/Subsequent Entry Biologic Revenue Share by Application in 2021
Figure 64. Global Bio Similars/Subsequent Entry Biologic Market Share Forecast by Application (2023-2028)
Figure 65. North America Bio Similars/Subsequent Entry Biologic Sales Market Share by Type (2017-2028)
Figure 66. North America Bio Similars/Subsequent Entry Biologic Sales Market Share by Application (2017-2028)
Figure 67. North America Bio Similars/Subsequent Entry Biologic Revenue Market Share by Country (2017-2028)
Figure 68. United States Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Canada Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Mexico Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Europe Bio Similars/Subsequent Entry Biologic Sales Market Share by Type (2017-2028)
Figure 72. Europe Bio Similars/Subsequent Entry Biologic Sales Market Share by Application (2017-2028)
Figure 73. Europe Bio Similars/Subsequent Entry Biologic Revenue Market Share by Country (2017-2028)
Figure 74. Germany Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. France Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. United Kingdom Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Russia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Italy Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Asia-Pacific Bio Similars/Subsequent Entry Biologic Sales Market Share by Type (2017-2028)
Figure 80. Asia-Pacific Bio Similars/Subsequent Entry Biologic Sales Market Share by Application (2017-2028)
Figure 81. Asia-Pacific Bio Similars/Subsequent Entry Biologic Revenue Market Share by Region (2017-2028)
Figure 82. China Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Japan Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. South Korea Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. India Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. Southeast Asia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Australia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 88. South America Bio Similars/Subsequent Entry Biologic Sales Market Share by Type (2017-2028)
Figure 89. South America Bio Similars/Subsequent Entry Biologic Sales Market Share by Application (2017-2028)
Figure 90. South America Bio Similars/Subsequent Entry Biologic Revenue Market Share by Country (2017-2028)
Figure 91. Brazil Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 92. Argentina Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 93. Middle East and Africa Bio Similars/Subsequent Entry Biologic Sales Market Share by Type (2017-2028)
Figure 94. Middle East and Africa Bio Similars/Subsequent Entry Biologic Sales Market Share by Application (2017-2028)
Figure 95. Middle East and Africa Bio Similars/Subsequent Entry Biologic Revenue Market Share by Country (2017-2028)
Figure 96. Turkey Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 97. Saudi Arabia Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 98. UAE Bio Similars/Subsequent Entry Biologic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 99. Methodology
Figure 100. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
